Biogen Falls as Forecast Cut and Top Drug’s Sales Disappoint

Updated on

Biogen Inc. shares plummeted after the biotechnology company lowered its forecast for 2015 profit and sales, revising expectations for growth as its top-selling multiple sclerosis drug faces tougher competition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.